The pCHSPC Fraction Exclusively Stimulates Increased Tube Formation

Slides:



Advertisements
Similar presentations
Effects of Human Circulating Hematopoietic Stem & Progenitor Cells on Angiogenesis in the C32 Human Melanoma Xenograft Mouse Model Dillon Etter, Larry.
Advertisements

The Role of Human Circulating Hematopoietic Stem and Progenitor Cells (CHSPCs) in Promoting Tumor Growth, Angiogenesis and Vascular Repair March 3rd, 2011.
Volume 15, Issue 6, Pages (June 2009)
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
Soluble factors from the notochordal-rich intervertebral disc inhibit endothelial cell invasion and vessel formation in the presence and absence of pro-inflammatory.
by Shawn W. Cochrane, Ying Zhao, Robert S. Welner, and Xiao-Hong Sun
A surrogate marker to monitor angiogenesis at last
Volume 5, Issue 2, Pages (August 2009)
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
Volume 25, Issue 9, Pages (September 2017)
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ–Dependent Apoptosis of Alloreactive CD4+ T Cells In Vitro and Reduce Lethal Graft-Versus-Host.
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,
Vascular Endothelial Cells Produce Soluble Factors That Mediate the Recovery of Human Hematopoietic Stem Cells after Radiation Injury  Garrett G. Muramoto,
A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome  Gerhard C. Hildebrandt, Krystyna.
Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.
Human Progenitor Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Increased Frequency in Comparison to Cells from the Same Donor Mobilized.
by Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A
Human CD4+CD25+ Cells in Combination with CD34+ Cells and Thymoglobulin to Prevent Anti-hematopoietic Stem Cell T Cell Alloreactivity  Dolores Mahmud,
Adoptive Cellular Therapy using Cells Enriched for NKG2D+CD3+CD8+T Cells after Autologous Transplantation for Myeloma  Kenneth R. Meehan, Laleh Talebian,
FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.
Volume 10, Issue 3, Pages (September 2004)
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Growth factors mobilize CXCR4 low/negative primitive hematopoietic stem/progenitor cells from the bone marrow of nonhuman primates  Nadim Mahmud, Hetal.
Imiquimod Inhibits Melanoma Development by Promoting pDC Cytotoxic Functions and Impeding Tumor Vascularization  Caroline Aspord, Laetitia Tramcourt,
Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15 by Lazar.
Exaggerated inflammatory environment decreases BMP-2/ACS-induced ectopic bone mass in a rat model: implications for clinical use of BMP-2  R.-L. Huang,
Volume 7, Issue 1, Pages (January 2005)
Volume 15, Issue 6, Pages (June 2014)
Volume 18, Issue 10, Pages (October 2010)
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
Volume 13, Issue 1, Pages (January 2006)
Volume 4, Issue 2, Pages (February 2003)
Volume 25, Issue 9, Pages (September 2017)
Volume 21, Issue 8, Pages (November 2017)
Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β-Thalassemia Major  Nikoletta Psatha, Andreas.
Volume 10, Issue 5, Pages (November 2004)
Clinically Relevant Expansion of Hematopoietic Stem Cells with Conserved Function in a Single-Use, Closed-System Bioprocess  Gerard J. Madlambayan, Ian.
Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice  Dapeng Wang, Yu Yu, Kelley Haarberg,
Volume 43, Issue 2, Pages (August 2015)
Ravindra Majeti, Christopher Y. Park, Irving L. Weissman 
Volume 9, Issue 1, Pages (July 2011)
Volume 22, Issue 1, Pages (January 2014)
Volume 20, Issue 13, Pages (September 2017)
David Traver, Koichi Akashi, Irving L. Weissman, Eric Lagasse  Immunity 
Kevin G. Haworth, Christina Ironside, Zachary K. Norgaard, Willimark M
Volume 4, Issue 2, Pages (February 2009)
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Volume 15, Issue 1, Pages (January 2009)
Volume 6, Issue 5, Pages (November 2002)
Volume 2, Issue 1, Pages (January 2008)
Volume 8, Issue 1, Pages (January 2011)
Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice  Rui Sun, Ruth A Gault, Lisbeth.
Volume 18, Issue 4, Pages (April 2010)
Tobias Maetzig, Jens Ruschmann, Lea Sanchez Milde, Courteney K
Moutih Rafei, Elena Birman, Kathy Forner, Jacques Galipeau 
Volume 25, Issue 4, Pages (April 2017)
Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response  Arup Garu, Gopikrishna.
Volume 20, Issue 6, Pages (June 2012)
Molecular Therapy - Methods & Clinical Development
Granulocyte colony-stimulating factor mobilizes dormant hematopoietic stem cells without proliferation in mice by Jeffrey M. Bernitz, Michael G. Daniel,
Volume 18, Issue 2, Pages (February 2010)
Molecular Therapy - Oncolytics
Alicia G Arroyo, Joy T Yang, Helen Rayburn, Richard O Hynes  Cell 
Volume 12, Issue 5, Pages (November 2005)
CD123 CAR T cells for the treatment of myelodysplastic syndrome
T cells expressing a KIR-CAR/Dap12 show potent in vivo antitumor activity that is resistant to the tumor-induced T-cell hypofunction observed with CD3ζ-based.
Presentation transcript:

The pCHSPC Fraction Exclusively Stimulates Increased Tube Formation Human Proangiogenic Circulating Hematopoietic Stem and Progenitor Cells Promote Tumor Growth in an Orthotopic Melanoma Xenograft Model Julie A Mund, Karen E Pollok, Jamie Case. Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA. Abstract Results II Figure 1. Schematic of C32 Melanoma Xenograft Model. Mice were sub-lethally irradiated with 300 rads and human CD34+ cells were then transplanted into NOD/SCID mice. Following 4 weeks of engraftment, peripheral blood was analyzed for human CD45 and then C32 melanoma cells were implanted on the flanks of the humanized mice with tumor growth and CHSPCs both being monitored. pCHSPCs are Mobilized into the PB Following Tumor Implantation and Correlates with Increased Tumor Growth. We previously identified a distinct population of human circulating hematopoietic stem and progenitor cells (CHSPCs; CD14-glyA-CD34+AC133+/-CD45dimCD31+ cells) in the peripheral blood (PB) and bone marrow, and their frequency in the PB can correlate with disease state. The proangiogenic subset (pCHSPC) play a role in regulating tumor progression, for we previously demonstrated a statistically significant increase in C32 melanoma growth in NOD.Cg-Prkdcscid (NOD/SCID) mice injected with human pCHSPCs (p<0.001). In our current study, we provide further evidence that the pCHSPCs possess proangiogenic properties. In vitro bio-plex cytokine analyses and tube forming assays indicate that pCHSPCs secrete a proangiogenic profile and can promote vessel formation respectively. We also developed a humanized bone marrow-melanoma orthotopic model to explore in vivo the biological significance of the pCHSPC population. Sub-lethally irradiated NOD/SCID, NOD.Cg-PrkdcscidIL2rgtm1Wjl/Sz (NOD/SCID/chainnull) or SCID/beige mice were transplanted with cord blood-derived CD34+ cells. Human cell engraftment was verified at 4 weeks post-transplant, C32 melanoma cells were then implanted in the flank and tumor growth monitored. Growth of melanoma xenografts increased more rapidly at 3-4 weeks post-tumor implantation in mice previously transplanted with human CD34+ cells compared to control mice. Increases in pCHSPCs in PB correlated with increases in tumor growth. Additionally, to determine if we could prevent the appearance of pCHSPCs in the PB, mice with humanized bone marrow-melanoma xenografts were administered Interferon-a-2b, which is used clinically for treatment of melanoma. The mobilization of the pCHSPCs was decreased in the mice with the humanized bone marrow-melanoma xenografts. Taken together, these data indicate that pCHSPCs play a functional role in tumor growth. The novel in vivo model described here can be utilized to further validate pCHSPCs as a biomarker of tumor progression. The model can also be used to screen and optimize anticancer/anti-angiogenic therapies in a humanized system. Results I Figure 3. Mobilization of pCHSPCs (AC133+) into the Peripheral Blood in Mice Harboring C32 Melanoma Xenografts. The CD34+ cells used to repopulate the marrow after sub-lethal irradiation (a). Peripheral blood, from NOD/SCID mice following transplantation with CD34+ cells was tested in mice with C32 melanoma xenografts, with representative plots at (b) 5 weeks post CD34+ transplantation/1 week post implantation of C32 cells, (c) 8 weeks post CD34+ transplantation with no C32 implantation, (d) 8 weeks post CD34+ transplantation/4 weeks post implantation of C32 cells, and (e) 10 weeks post transplantation/6 weeks post implantation of C32 cells. pCHSPCs (red arrow) are mobilized from the bone marrow into the peripheral blood following 4 weeks after C32 melanoma flank implantation (pCHSPCs at week one versus week 4 post-implantation of C32 tumor cells, p<0.005). Figure 5. Interferon a-2b-Mediated Decreases in the ratio of pCHSPC:nCHSPC in Transplanted Mice with C32 Melanoma Xenografts. NOD/SCID/gchainnull mice were first transplanted with human CD34+ cells and then the C32 melanoma was implanted on the flank 4 weeks post-transplantation. Following two weeks of C32 melanoma unrestricted growth, some mice were treated with Interferon a-2b (Intron-A; 50,000U X 3 times per week) and tumor volume was measured via caliper over time (a). There were decreased pCHSPCs in the peripheral blood following Interferon a-2b treatment (b). The pCHSPC Fraction Exclusively Stimulates Increased Tube Formation Mobilization and engraftment were checked in 3 strains of mice: NOD/SCID/γchainnull, SCID/bg and NOD/SCID. Interestingly, the NOD/SCID/γchainnull had better CD34+ engraftment and had better emergence of immature and mature hematopoietic cells in both the PB and BM compared to SCID/bg. Following implantation of C32 melanoma cells, the peripheral blood has few pCHSPCs compared to nCHSPCs (Figure 3b). If no melanoma was implanted, there is no increase in pCHSPCs in the PB (Figure 3c). As the C32 melanoma tumors begin to increase their size around 4 weeks, the pCHSPC fraction increases in the PB (Figure 4). Conclusions Aim Proangiogenic circulating hematopoietic stem/progenitor cells (pCHSPCs) increase tube formation in vitro and secrete some proangiogenic factors. Orthotopic models of human cancers are necessary and powerful tools for understanding malignancy. The tracking of the nCHSPC and pCHSPC fractions in both tumor and non-tumor bearing mice validates the pCHSPC as a useful biomarker of tumor progression and treatment efficacy in anticancer therapy studies. We have previously shown a decrease in pCHSPCs in pediatric solid tumor patients undergoing successful chemotherapy treatments, and have replicated this study using treatment with Interferon α-2b. This orthotopic model, together with the pCHSPC biomarker, allows for screening and optimizing of anticancer/anti-angiogenic therapies in a humanized system. To further characterize the pCHSPC fraction of the PB and bone marrow and to develop an in vivo orthotopic model of melanoma to demonstrate the utility of the pCHPSC as a biomarker of active angiogenesis and treatment efficacy. Methods Cord blood (CB) MNCs expressing the CD34 antigen were immunomagnetically selected using the Magnetic Cell Sorting (MACS) system, then sorted using fluorescence for CD14-CD31+CD34brightCD45dimAC133+ cells (proangiogenic CHSPCs) and CD14-CD31+CD34brightCD45dimAC133- cells (non-angiogenic CHSPCs). NOD.CB17-Prkdcscid/J (NOD/SCID) mice were sub-lethally irradiated and CB derived CD34+ cells were transplanted. After 4 weeks, PB was analyzed for human CD45+. The mice were then subcutaneously injected with 2x106 C32 human melanoma cells (ATCC), with tumor growth being monitored and CHSPCs measured by flow cytometry (Figure 1). 7500 ECFCs were plated either alone or with pCHSPCs or nCHSPCs for Matrigel tube formation; 7500 of each CHSPC population were also plated alone to asses tube formation (Figure 2). Flow cytometry analysis of the pCHSPCs and nCHSPCs in the PB was assessed at baseline, 1, 2, 3, 4, and 6 weeks post tumor implant. Additionally, BM was analyzed at harvest (Figure 3). Tumor growth was monitored over time by caliper and the volume determined by the following formula: mm3 = (width)2 x length x 0.5. The fold increase in tumor growth was determined by comparing tumor volume over time to the base line tumor volume. At the end of the experiment (4-6 weeks), mice were euthanized, tumors harvested, and the weight of each tumor determined. In some experiments, Interferon α-2b (Intron A; 50,000U X 3 times a week) was administered via subcutaneous injection for 6 total doses. Flow cytometry analysis was performed for pCHSPCs and nCHSPCs at baseline, post Interferon α-2b treatment and at harvest (Figure 5). Figure 4. Increased tumor volume following CD34+ transplantation. NOD/SCID mice were initially sub-lethally irradiated and then injected subcutaneously in the flank with C32 cells at 4 weeks post CD34+ transplantation. Tumors in mice transplanted with CD34+ cells were significantly larger than tumors in sham transplanted mice as indicated by a significant main effect for group in the ANOVA (F[1,60] = 11.2, p < 0.01). Post-hoc analysis indicated that tumors in CD34+ transplanted mice were significantly larger beginning on day 31 post-implant (*p<0.05, #p<0.001). Moreover, tumors in CD34+ transplanted mice grew at a significantly faster rate as indicated by a significant group-by-days interaction (F[9,69] = 6.2, p<0.001). Future Study Figure 2. Matrigel Tube Formation. Graph of all populations tested for tube formation (a). Tube formation was increased with the addition of the pCHSPCs with no difference between ECFCs alone and ECFCs with nCHSPCs (p<0.008). Representative photomicrographs of tube formation assays comparing nCHSPCs alone, pCHSPCs alone, ECFCs alone, ECFCs with nCHSPCs, and ECFCs with pCHSPCs (b). Future examination of these cells to identify the specific molecular pathways for promoting tumor angiogenesis may be insightful and permit a better understanding of mechanisms for blocking tumor angiogenesis. Investigating how to expand and maintain proper functional characteristics of the pCHSPC and nCHSPC populations and identify where in hematopoietic differentiation Neither pCHSPC or nCHSPC cells formed tubes when plated without ECFCs. ECFCs plated with pCHSPCs had more robust tube formation than ECFCs alone or ECFCs with nCHSPCs (p<0.008, Figure 2a) A bio-plex performed on the conditioned media from plated pCHSPCs showed secretion of Eotaxin, G-CSF, GM-CSF, VEGF, IL-1ra, IL-2, IL-9, IL-15, IL-17, INF-γ, MIP-1β and RANTES. The pCHSPCs did not have detectable levels of IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, basic FGF, IP-10, MCP-1, MIP-1α, PDGF-BB, or TNF-α. Interferon α-2b Prevents the Mobilization of pCHSPCs in Response to C32 Melanoma Acknowledgements Following implantation of C32 melanoma cells, the pCHSPC:nCHSPC ratio was assessed before and after 2 weeks of Interferon α-2b treatment. The ratio was decreased by 15% without decreasing tumor size. There was no difference in CD45+ cells in the bone marrow of mice transplanted with human CD34+ cells with or without melanoma and regardless of Interferon α-2b treatment. Similar decreases of pCHSPCs are seen in pediatric solid tumor patients. We acknowledge the assistance and state-of-the-art facilities from the Angiogenesis, Endothelial and Pro-Angiogenic Cell Core, the In Vivo Therapeutics Core, and the Flow Cytometry Facility at the Indiana University Simon Cancer Center at Indiana University School of Medicine. Grant support: American Cancer Society IRG-84-002-25 (J.C.), Showalter Trust Fund ERA 31948 (J.C.), NIH/NIDDK P30DK090948 CEMH (J.C., J.A.M and K.E.P.), RO1 CA138798 (K.E.P.) and the Jeff Gordon Research Foundation (K.E.P.).